Dolnicka Agnieszka, Fosse Vibeke, Raciborska Anna, Śmieszek Agnieszka
Laboratory of Preclinical Research and Cell Transplantation "In VetBio" at the Applied Biology Center, Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland.
Department of Clinical Science, University of Bergen, Jonas Lies vie 91B, 5021 Bergen, Norway.
Int J Mol Sci. 2025 May 28;26(11):5152. doi: 10.3390/ijms26115152.
Osteosarcoma (OSA) is a naturally occurring malignant bone tumor in both humans and canines that is characterized by aggressive local behavior and a high propensity for metastasis. Despite advances in diagnostic methods and therapies, long-term survival rates have remained stagnant, underscoring the great need for the development of biomarkers serving in the prognosis and diagnosis of OSA across species. Biomarkers, molecular indicators of disease presence or progression, are pivotal tools in oncology, offering the potential to determine risk stratification, guide targeted therapies, and monitor treatment response. This review provides an in-depth analysis of the current landscape of OSA biomarkers, highlighting diagnostic and prognostic markers identified across species. We highlighted the role of biomarkers, including protein, cellular, metabolic, imaging, genetic, and epigenetic markers, in osteosarcoma diagnosis and prognosis and categorized them across multiple domains. Furthermore, this review explores the utility of the canine model in osteosarcoma research, emphasizing its relevance to human OSA due to comparable diagnostic approaches, prognostic indicators, and clinical manifestations. With this review, we aim to demonstrate that integrating biomarker research across species can deepen the understanding of osteosarcoma pathogenesis and advance knowledge of its underlying biology, ultimately paving the way for precision medicine strategies that benefit both human and veterinary oncology.
骨肉瘤(OSA)是一种在人类和犬类中自然发生的恶性骨肿瘤,其特征是具有侵袭性的局部行为和高转移倾向。尽管在诊断方法和治疗方面取得了进展,但长期生存率一直停滞不前,这突出表明迫切需要开发用于跨物种骨肉瘤预后和诊断的生物标志物。生物标志物是疾病存在或进展的分子指标,是肿瘤学中的关键工具,具有确定风险分层、指导靶向治疗和监测治疗反应的潜力。本综述对骨肉瘤生物标志物的当前状况进行了深入分析,重点介绍了跨物种鉴定的诊断和预后标志物。我们强调了生物标志物在骨肉瘤诊断和预后中的作用,包括蛋白质、细胞、代谢、成像、遗传和表观遗传标志物,并将它们分类到多个领域。此外,本综述探讨了犬模型在骨肉瘤研究中的实用性,强调由于其在诊断方法、预后指标和临床表现方面与人类骨肉瘤具有可比性,因此与人类骨肉瘤相关。通过本综述,我们旨在表明跨物种整合生物标志物研究可以加深对骨肉瘤发病机制的理解,并推进对其潜在生物学的认识,最终为造福人类和兽医肿瘤学的精准医学策略铺平道路。